MDB Capital (MDBH) Q3 2026 Earnings Call Transcript

Source Motley_fool
Logo of jester cap with thought bubble.

Image source: The Motley Fool.

DATE

Tue, Nov. 17, 2026

CALL PARTICIPANTS

  • Chief Executive Officer and Co-Founder - Christopher Marlett
  • President and Head of Community Development - George Brandon

TAKEAWAYS

  • Fee Income -- $4.2 million for the first nine months, contributing to a reduction in the overall cash burn rate.
  • Operating Cash -- $8.3 million as of the end of the quarter, including deposits for clearing operations.
  • Manufacturing Costs -- Under $1,000 per kilo for eXoZymes products, representing a reduction from initial cost estimates of $3,500 per kilo.
  • Patent Processing Capacity -- 1,000 patent applications per year at PatentVest, utilizing AI-enhanced business processes and Arizona legal structures.
  • Seed Round Financing -- $19 million for Paulex Bio, supporting the development of its diabetes treatment platform.
  • Outstanding Shares -- Under 11 million shares, which management indicated creates high valuation leverage if individual assets reach inflection points.
  • Clinical Trial Timeline -- Dec. 2026 for the first patient dosing at Paulex Bio, representing a two-month delay from the original September target.
  • Clearing Broker-Dealer Market -- Approximately 100 firms in the U.S., a limited pool that management believes increases the strategic value of Public Ventures.
  • Operating Expense Reduction -- Plan to fund and partner Public Ventures and PatentVest separately to lower the parent company's cash utilization.
  • Asset Distribution Target -- 2027 for the planned distribution of subsidiary assets to shareholders as companies hit commercial inflection points.
  • Product Pipeline -- Multiple compounds at eXoZymes, including NCT and a planned spin-out for synthetic cannabinoid development.
  • Historical Acquisition Benchmark -- $2.9 billion for Provention Bio, cited by management as a success metric for its previous work in the diabetes space.
  • Revenue Growth -- 60% for Buda, a juice company in which MDB holds an equity interest, despite current market valuation pressures.
  • Development Duration -- Two and a half years spent training analysts and paralegals to operate PatentVest's proprietary IP law platform.
  • Employee Count -- 14 employees at the parent level, maintaining a lean organizational structure.
  • Strategic Asset Count -- Four primary assets including Public Ventures, PatentVest, eXoZymes, and Paulex Bio.
  • Global IP Law Market -- $30 billion, which PatentVest aims to disrupt by integrating business strategy with intellectual property law.
  • Drug Discovery Speed -- Days rather than years to prototype new compounds at eXoZymes by utilizing AI-driven enzyme toolkit analysis.
  • Acquisition Reference -- $7 billion for a company with a single approved cannabinoid drug, used by management to highlight market potential.

Need a quote from a Motley Fool analyst? Email pr@fool.com

RISKS

  • Marlett stated, "the market has been a bit tumultuous and a lot of uncertainty out there," noting that hospitable conditions for small companies currently do not exist.
  • Marlett warned that the company is currently "2 months behind" its original internal schedule for dosing patients in the Paulex clinical trial.
  • Marlett noted, "We're still doing financings for companies like eXoZymes, Paulex, and we can't control the markets around those," highlighting execution risk related to capital market volatility.

SUMMARY

MDB Capital (NASDAQ:MDBH) reported a strategic transition toward leaner operations by seeking external financing and partnerships for its primary subsidiaries to reduce internal cash utilization. Management stated that the company is currently focused on bringing its four core assets—Public Ventures, PatentVest, eXoZymes, and Paulex Bio—to value inflection points to facilitate distributions to shareholders. The company indicated that the current market environment has limited its ability to launch new enterprises, leading to a concentrated focus on these established technology and financial services platforms. Management reported that technical milestones were reached during the quarter, particularly in cell-free synthetic biology manufacturing and AI-integrated intellectual property law.

  • The company is in active discussions with multiple partners to scale its self-clearing platform, Public Ventures, which Marlett indicated is ready to expand into stock loans and margin trading.
  • PatentVest has integrated 30 defined business processes with AI, which Marlett stated allows the firm to complete patent application tasks in a single day that previously required months.
  • Marlett indicated that eXoZymes is targeting partnerships with large pharmaceutical companies to bring its proprietary nutritional and drug compounds to market.
  • Paulex Bio is preparing for a potential public listing in the first half of 2027 while advancing safety and efficacy trials for its beta cell regeneration drug.
  • Marlett stated, "We think we can create a lot of value. We think we can attract great lawyers because great lawyers will have to be on a platform like this."
  • The company intends to deliver asset distributions to shareholders throughout 2027, with eXoZymes highlighted as a likely first candidate due to its current public status.

INDUSTRY GLOSSARY

  • Public Ventures: The company's self-clearing broker-dealer subsidiary focused on microcap and small-cap companies.
  • PatentVest: An intellectual property law firm subsidiary that utilizes AI and business intelligence to process patent applications.
  • eXoZymes: A synthetic biology subsidiary utilizing cell-free enzyme processes to manufacture nutritional and pharmaceutical compounds.
  • Paulex Bio: A drug development subsidiary focused on therapies to regenerate insulin-producing beta cells in diabetic patients.
  • Clearing Broker-Dealer: A financial intermediary that handles the execution, settlement, and delivery of securities transactions.
  • GLP-1: Glucagon-like peptide-1, a hormone used as a target for a class of drugs treating type 2 diabetes and obesity.
  • Beta Cells: Specialized cells in the pancreas responsible for the production and release of insulin.

Full Conference Call Transcript

Tony Dammicci: Welcome, everyone, to the MDB Capital Holdings Third Quarter 2026 Update Webinar. Thank you for joining us today. [Operator Instructions] Before we begin the formal presentation, I'd like to remind everyone of several important things. Today's webinar is being recorded. [Operator Instructions] Please remember that statements made on this webinar may contain provisions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You're cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation.

Also, please be aware that we are not obligating ourselves to revise or publicly release results or any revision to these forward-looking statements in light of new information or future events. Throughout today's discussion, we will attempt to present some important factors relating to our business that may affect our predictions. You should also review our most recent Form 10-Q for a more complete discussion of these factors and other risks, particularly under the heading of Risk Factors. A press release detailing these results, which crossed the wire this afternoon, is available in the Investor Relations section of our website, mdb.com. A replay of this call will also be provided later on, on mdb.com.

Your host today is Chris Marlett, Chief Executive Officer and Co-Founder of MDB Capital Holdings. He'll be joined later by George Brandon, MDB President and Head of Community Development. Chris will lead a business update for the quarter ending September 30, 2026, and subsequent developments. So at this time, I'd like to turn the call over to Chris Marlett.

Christopher Marlett: All right. Thanks, Tony. Well, thanks, everyone, for joining today. I know the market has been a bit tumultuous and a lot of uncertainty out there, and I appreciate you all taking the time today to join us for this call. And I'll get right into the update. So I'm going to be decidedly upbeat because I really believe that what we set out to do when we started MDB and took it public was to generate big ideas. And our whole history has been based on creating new enterprises and giving these big ideas access to public liquidity.

Albeit the markets have not been super hospitable to small companies, we have no control over that, but we do have control over what we do. And many of the companies or most of the companies in our history, we would look at these IP-centric companies that we believe have a real moat around them. And then, we've also launched some other companies that we believe are transformative that were part of our platform, which we've talked a bit about historically, which is our self-clearing broker-dealer platform and our IP law firm, which we're very proud of. We created the structure of an LLC so that we could distribute out assets.

And that's exactly what we still intend to do is distribute these assets as soon as these companies hit an inflection point. And we think that some of these companies are very near an inflection point in why we are hopeful to be distributing out these assets very soon. We have executed on those ideas. We have not executed on launching more companies purely because of the backdrop of the current market. So when you look at, as we say, constrained access to capital and depressed valuations, we were hoping to launch 2 to 3 to 4 big ideas a year, which has just not been feasible in this market environment.

But with the companies we have launched, we're very proud of them, and those companies have executed on their mission to get to commercialization and close to a big inflection point. So our road ahead right now with the market backdrop is to really make sure that the 4 key assets we have get to a value inflection point.

And as we've talked about historically, it's Public Ventures, our clearing platform; PatentVest, our disruptive new age IP law firm; eXoZymes, which is, we believe, the leader in cell-free synthetic biology, which we think is going to be a huge market; and Paulex, folks that we have built a company with before that disrupted diabetes, and we believe this next drug or platform will disrupt diabetes again. So our core objective with all these assets has been to bring them to a value inflection point, and we're putting most of our efforts in helping those companies to get there at this time.

We really need to see these companies perform, and we're very excited about where they sit today and their ability to impact the markets that they're going to be serving. We are going to be leaning up. We're not blind to the market environment. So we need to run a much leaner shop, and we'll be cutting expenses while we're also liberating ourselves of current cash OpEx by funding and partnering Public Ventures and PatentVest going forward. We believe significant value has been built, and our teams have done magnificent work. They really have executed on standing up these companies and getting them close to commercialization.

So our job is really to help each one of these companies get to that value inflection point as soon as humanly possible. So going to all 4 of those -- the various opportunities, talk about why we did it, what we've accomplished and what we see as the road ahead. And so Public Ventures was a super simple concept. All of these companies that finance young microcap or small-cap companies, had been challenged in the fact that clearing firms really didn't want to support these type of firms anymore. We saw there was a huge opportunity to serve this marketplace. Obviously, most of investor capital has been going upmarket into very large companies.

And now, the market has largely been dominated by these companies. A lot of them, they're serving the AI marketplace. And the small companies have just been sort of forgotten for the most part. And we don't think that's sustainable. We think ultimately, money will rotate back into this asset class. And we've always believed that you need to have a purpose-built clearing firm to serve that marketplace. We feel exact same today as we did when we started it, but we've actually executed on getting it stood up. We also see that digital is going to become a very big part of it, whether that's tokenization or crypto-related assets.

We do believe that investors are looking for different ways to invest in these companies. And it's also a global -- it's a globalization situation. We have so many foreigners investing in the U.S. capital markets today and increasingly looking for easier ways to do that, whether that's through tokenized securities or other platforms that enable a lot less friction in investing in these kind of companies. We have the ability to do that and serve the -- let's call it, the microcap or small cap marketplace. We don't think it's easy to copy. We think that our intellectual capital we have in this marketplace is significant. We've been doing this for 30 years in this marketplace.

And in fact, we have tremendous experience in doing this that nobody else is really -- there's very few other firms that have as much experience in this sector as we do. And getting a clearing license takes years to earn and actually get it operational. And our firm has done it very cost effectively and very efficiently. So we began this sort of, I would say, almost 5-year journey to actually get this thing set up to where we could start clearing offerings. And for those of you that have used MDB Direct and actually participate in the offerings, you see it works great. We built a great, solid technical platform.

But now it's time for it to expand its capabilities. And there are many ways that clearing firms make money, whether it's stock loan, margin and more active trading. Most of our accounts are not big time active traders. And so we are in the discussions with numerous folks that are looking to have a clearing platform and utilize the strength of what we've built and our knowledge in this marketplace as well as taking advantage of our trained team in Latin America, where we can operate not only with higher quality.

And those of you that have had a chance to deal with our operations team, you know that we have a very professional team that's doing a great job, and we can do that in a very cost-efficient way. It's very hard to build a clearing firm in New York City today, expensive rent, expensive people. It's not the place to build it. And we think we've built something super valuable with Public Ventures, and we couldn't be more proud of what we've done. So where it stands is that we really have something that is ready set for someone that has visions for building these big platforms.

And we've seen recently some firms transact, where we've seen companies like Kalshi just go and buy a brokerage firm to be able to do something similar to this. Well, it turns out there's only 100 -- approximately 100 clearing broker-dealers in the U.S. It's not -- as we know, it's not easy to get. And so I think that now we are at sort of this inflection point, where we need to partner with someone to really bring scale to it. We've been in discussions with several highly qualified folks that understand how to scale clearing operations.

They see the value in what we've created, and we hope to conclude a transaction that we think will help realize the value of Public Ventures going forward. So we really see this as the next evolution of how new enterprises will enter the market. Even though today it is not the asset class of choice, we believe that money will rotate back into the sector as small companies need access to capital, we see the public markets as being a great place for that. PatentVest. We saw a distinctly huge opportunity.

What we saw in the area of patent law when we were starting new companies, especially companies that needed to file 50 or 100 patents to put a moat around their technology platform, was it was not only very costly to do, but it was very difficult to do because no law firms really marry business intelligence with IP law. And so when Arizona opened the door to enable this to be run in a business-like way as opposed to thinking about IP as a legal process, we thought of it as a business process. We saw this as a huge opportunity. And the team led by Javier Chamorro has done a phenomenal job of standing up this law firm.

And we brought on several lawyers. We've trained paralegals. We have an entire analyst team that provides that critical sort of associate layer. And now, of course, with AI, it is going to be supercharging this effort. So what happened in the middle of building this, the great news, is we were building this to serve a $30 billion global market that we knew was not being served by law firms currently and AI just dramatically sped up the disruption. And it's -- I don't think that IP law is going to look anything like it has for the last 5 years. It's going to be very, very different going forward.

And what we see is the key part of it is integrated business strategy, IP strategy, R&D and have that in a really unified and connected way. And I'm 100% confident no law firm has delivered upon that, and we are now ready to do that. And so what it took was training these analysts and paralegals with the lawyers to work on in this unified process, of course, organizing it under Arizona law. And our technology is we took 30 defined processes that we were building historically in a digital place, but without AI. What happened with AI is it just supercharged the entire effort. And it dramatically lowered our technology development costs.

But we had all these defined processes that were put in place that enabled us to be super efficient. And now with AI, we are achieving things that have never been achieved before in the practice of IP law. We can take something from an invention, put it into business context, IP context, develop claims that can be granted by the patent office, examine those claims. And when we file it, we can literally have demonstrated we could do this in 1 day. This would take months before to happen. It is the most disruptive thing I've ever seen.

We've got a company like eXoZymes that needs to probably file 100 patent applications a year, there's no way that, that can be done both cost effectively and efficiently in any kind of way. We now have the ability to process 1,000 patent applications a year in a legally compliant manner. And legally compliant is really the most key aspect of what we're talking about because you can't just put things into ChatGPT or Claude as an inventor or as a lawyer and get -- and effectively process the whole application to grant a patent in that way. And so our team has put together an incredible platform that is legally compliant, and we are now rolling it out.

And like I said, we can take an invention and put it into a legal and business context, instantly create those claims, give the company R&D road map, and the efficiency and cost is something that's never been seen before. And I really do believe we have a real lead over other people, and then, it will not become easily replicated because we were built to do it this way from the very beginning. And so where it stands, the tech stack is built. The team is trained, and it's no longer just talk. We can demonstrate it.

We can go to companies that are processing hundreds of patents a year and say, we can absolutely do a better job than that big name law firm, and we can demonstrate it. And we are actually -- to actually prove it, we've actually taken some of the patent applications that are public and examined them and showed them how bad the quality is that these other law firms are filing of their patents and how we can improve it. It really is disruptive. And we're sitting down with new potential clients. We can actually demonstrate it to them, which again is, I think, going to be very disruptive.

So we're going to complete a financing to scale up that marketing, bring in salespeople that can make it painfully obvious to the client that they need to transition their business to PatentVest. And we think that a growing client base can get this to profitability fairly quickly on not a lot of capital. So we think we can create a lot of value. We think we can attract great lawyers because great lawyers will have to be on a platform like this. And we're super excited about it. We believe that the practice of law will never be the same, and we're going to be a leader in this segment.

So I really want to thank the team, the hard work that the team at PatentVest has done to get us there. It's been concentrated 2.5 years of hard work to get there, but we're there, and we're ready for scale, and it's an exciting time. And so eXoZymes, what did we see with eXoZymes? It was super simple. Everybody knew that synthetic biology was the future of being able to create natural products that synthetic chemistry could not create or could not be extracted from the natural products in any kind of economic way. And so there were companies like Ginkgo and others that went to multibillion-dollar valuations, Amyris, Zymergen.

And what they proved was that they couldn't scale in a cell-based environment, which is through fermentation. What we had seen from the scientists at UCLA when we spun it out was that taking a cell-free process with just enzymes that this was promising and could be done. Well, in fact, the team has now proven it and has proven that the manufacturing process can scale and taking it beyond our first product and now creating a whole pipeline of products. So this has been a monumental accomplishment by the team at eXoZymes.

While the market has not yet recognized it yet, I can tell you, being on the Board, being there day-to-day, I can see that we have, also with AI, been able to rapidly scale the process of not only finding new compounds that we can make, but also getting them to manufacturing at a price that nobody thought would be possible before. So the company has shown not only scale-up, but also has shown scale-up at an unprecedented cost so that things that we would start off thinking, well, maybe we can make it for $3,500 a kilo, we can make it for now under $1,000 a kilo. That's really important when you're creating a nutritional supplement.

People can't pay $5 a day to take a nutritional supplement. It's got to be effective, and it's also got to be cost effective as well. And now we've been able to achieve that, not only with NCT, and we're now believing we can achieve it with other compounds as well that have great scientific validation that we believe could sell hundreds of millions, if not billions of dollars of product going forward and could be some of the biggest nutritional supplements ever launched. So there's a whole host of numerous compounds in the pipeline. And these nutraceutical companies and pharma companies need new compounds.

If you're a nutraceutical company and you're great at marketing nutritional supplements, you need something that's proprietary that nobody else has because you're not going to make any money selling vitamin D when there's 50 people selling vitamin D. You need new compounds that are proprietary, and eXoZymes can deliver that. Pharma, as you can see, is getting desperate as they're facing patent cliffs, and they're starting to buy companies for very large valuations that are very early in development. And so we are very confident that we can show them new compounds that have great scientific groundings underneath them or foundations underneath them that affect pathways that they know exist.

And so we're super excited about our ability to sit down with them and actually get to partnerships. Those partnerships are critical to getting these compounds to market because we're in the business of discovery and manufacturing, not in the business of actually launching these products. So those partnerships will bring scale to those. And I think you'll see some announcements shortly of relationships that will start to show that these are going to be marketed by other companies. So we believe these compounds can create billions of dollars of value, potential market value for eXoZymes and the partners.

And that's never really been possible in synthetic biology before, and you could never tell it from the stock price, but we do believe that it will get recognized. It is real. Anybody that wants to go visit the company, bring the most brilliant scientists you want to the company to go see it in person, we encourage you to do it. This is an extraordinary opportunity that we're very proud of. And lastly is Paulex Bio.

So Paulex, if you remember, we started the company with folks that we started Provention with that was a big success for us, a company that pioneered treatment of type 1 diabetes or helping delay or prevent type 1 diabetes through a drug that people had a lot of questions about, but it actually got approved. It worked, and the company got bought for $2.9 billion. And we worked with them to license a new drug that we're super excited about that will effectively hopefully enable people to regrow beta cells to make insulin again. So whether it's a type 1 diabetic or a type 2 diabetic, obviously, the market is huge.

It also fits really where major drug companies are looking for things. It's a small molecule. So it's a pill. It's not a biologic. It's very, very different than the road we had with Provention, which was a biologic, which was difficult to manufacture and difficult to dose as well. And so that enables what we say is asymmetric upside where if this pill works, the kind of return to our investors because of the promise and how it will fit with big pharma is really potentially very huge. And so as I said, we worked with them to license that drug from Mount Sinai and do a $19 million seed round.

We're probably about 2 months behind on -- we were looking at sort of September to dose our first patients in the clinical trial, took a little bit longer, and it looks like December is when we'll start to dose the first patients for safety, which we think is a very big milestone. And so we own a very nice piece of this company. And we have planned, we filed a registration statement confidentially.

We've also -- we do believe that the company would like to go public in the first half of next year, and we're working toward that process now, and we hope to see that the company is public as well as hitting the critical milestones of safety and potentially efficacy by showing that beta cells can be regrown. So as I said, the first milestone is safety, and we hope to be able to start to show that here very soon. And because this drug in preclinical studies is potentiated by GLP-1, it actually dramatically increases the effectiveness of it. We think it's a natural to be partnered with the pharma companies that are battling out in the GLP-1 space.

And we know that they need to have something that's unique and differentiated like this drug to give them a seat at the table in this new space that is turning into a potentially $100 billion market and growing over the next few years. So for the first 9 months, we had fee income of about $4.2 million. It's up from last year. So that ameliorated our burn a bit this past year. And so we kept costs relatively the same. And now through spinning out and effectively funding PatentVest and Public Ventures separately, we can bring our cash utilization down significantly.

And so right now, we're working on those 2 financings and spinning those out and partnering those out, as I've discussed earlier, which dramatically extends our runway. We had about $8.3 million in operating cash. We had some other deposits for clearing and things like that, that increased that cash position. But our goal is to reduce that operating spend so that we're not having to raise additional capital to extend our runway to get these things to a value inflection point. So as the largest shareholder, I can tell you the last thing I want to see is dilution.

And I want to make sure that we get these things to a value-creating point and then distribute those -- that value out to the shareholders as soon as humanly possible. So -- and again, to reiterate, the structure was set up to do that. We're not going back on that promise. We want to deliver these assets out. And I think that we expect to have distributions in 2027 of those assets to the shareholders. And we're right now reviewing that with the Board about how to do that, when to do that. But our goal is to deliver as much out to the shareholders in 2027 as possible.

And we hope to have some important updates on that shortly. So while I'm decidedly upbeat and I'm very excited about what we've done in launching these 4 companies, I also have to -- we also have to manage risk. And the risk is we're still doing financings for companies like eXoZymes, Paulex, and we can't control the markets around those. And so the timing of those transactions and financings are important. And we're working hard on that. We're in the midst of spending a lot of our time focused on that area.

The science, I think the science is now well established at eXoZymes, and I think we will start -- the science is well established at Paulex, but there are some critical milestones with both safety and efficacy for Paulex that we're going to see in the very short term that will impact dramatically the valuation of these -- of that company. We obviously have -- concentration in these assets can be good and bad. But I think that we have 4 assets, if any one of them work out great, we believe that it could create multiples of our stock -- current stock price.

If you think about eXoZymes or Paulex or any of these going to significant valuations, it has a big levering aspect on our stock being that we have just under 11 million shares outstanding. So we're still very hopeful that at least one of them works out. If one of them works out, it could be great. If all of them work out, it will be phenomenal. The markets for small public companies, I don't have to keep reiterating that. You guys know what that's like. We've seen a company like Buda that we don't have a huge equity interest in, but we love the company, and they've done nothing but perform. They have crushed it.

They've just announced earnings this week. Their revenues were up 60%. Earnings were up great. They are -- I mean, we are completely convinced that fresh juice is going to be in every major supermarket in the country, and they're going to be leading that charge. And yet, the stock went down on unbelievable earnings. And so that we can't control, but we're super proud of what they've done. They've done exactly what we expected them to do. What we didn't expect was that people don't care right now. But that -- we don't think that, that will persist forever. So again, we really love what our companies are doing. They've all have been moving things forward very well.

Even, again, another company we don't have a huge equity position in like HeartBeam, this thing is what appears to be super close to being approved for heart attack detection, could save millions of lives, could be everywhere, yet the market is just worried about financing risk, and it's just worried that maybe they won't get there. And we've seen this before. And we've seen it where it gets dark like this. I mean, today, I mean, I couldn't tell you that like right now, it seems like people are throwing in the towels on these things.

And maybe it goes lower, I don't know, but I certainly don't think that these great companies are just going to be totally ignored forever. So the markets have been confounding for us and what have you. But again, I can't control the markets, and we're very hopeful that we're near the bottom. And I think on execution, these business development partnerships are super important. I'm working most of my time right now in making sure we find the right partner for Public Ventures that we -- and Javier and team are doing a great job at PatentVest. They're at a legal tech conference right now.

They're talking to a number of companies that are interested in partnering with PatentVest as well as attorneys that want to join the bench and companies that are looking for a unique solution to prosecute IP. So a lot of execution needs to be done there, and I know the team is working very hard after having built a great platform. Also in -- with eXoZymes, we've got to get some deals done with marketing partners to sell these compounds that we're going to be putting into production shortly. And I think with Paulex, execution on the clinical trial and then ultimately, probably partnerships with big pharma that are going to want to bring that to the global medical landscape.

So with that, we have been in the business of turning ideas and what we think are valuable assets into enterprises. None of that has changed. We've got 4 very valuable enterprises in our mind, and we're excited to get these things to commercialization. It's not been easy. It's very tough. We are buckling down. We are scratching to get these things lifted and where we think are close on several of them. So we remain optimistic, albeit sanguine about the current environment that we're in. So with that, George, I'll turn it over to you to handle questions.

George Brandon: There are some questions. Yes, you can -- Chris, you may want to pull them up as well. And I want to make a comment that we are in the middle of financing with eXoZymes under an S-1 that's been filed. I would have you take a look at that S-1. There's a lot of information in there. If you haven't had a chance to look at the presentation that management has made here, there is a recording from NetRoadshow that I think we're going to try to put out to all of our shareholders and account holders tomorrow, and you can have an opportunity.

A lot of the questions I have in the chat board are regarding eXoZymes in that presentation. I just want to make sure that we're under this S-1 and this financing right now. So we really can't do much as far as going over and above what's stated in the S-1. But that said, Chris, one of the questions is on cannabinoids. Can you talk a little bit about that market? And what you see as far as what eXoZymes could do in the cannabinoid market?

Christopher Marlett: Yes. Cannabinoids are super interesting. We'll see, I think, both at a federal level and state level, it's been constrained because cannabinoid development has been -- I wouldn't say a dirty word. It's just been, I think, muddled. And so it's been held back from a nutritional supplement perspective. But from a pharmaceutical perspective, it has -- I think it was constrained as well, but I think it's starting to gain a lot of appeal because you've got the CB1 and CB2 receptors that are on so many of your cells in your body, and these compounds have been shown to do lots of things, whether it's deal with all kinds of medical conditions.

And I think the company has demonstrated that they have the only synbio platform that can actually manufacture these as drugs or as nutritional supplements. And so we're pretty excited about it because there's so much scientific research that's already been done on cannabinoids, but a lot of them just couldn't be made, and we can. So we're hoping that we could spin out a new company out of eXoZymes at some point to serve that market because we see it as a multibillion-dollar market in the area. There's one cannabinoid that's been approved that is doing over $1 billion in sales and got bought for about $7 billion. We think we can create multiples of those potentially.

And so it's a super exciting platform potential amongst a lot of the other things that are being developed at eXoZymes.

George Brandon: So a question about the AI drug designing and the whole frontier of new drugs that AI is discovering, and where does eXoZymes fit in with these AI companies on that?

Christopher Marlett: Yes. The great thing about these tools companies, whether it was PatentVest or now eXoZymes or even what we're doing at MDB, we have processes that when we would look at a company, to give you an example now, we would look at a Newco, we would get into a data room of a company looking for financing. And it would take us months to complete diligence to see if we want to get behind it. In some cases, we're able to rule in and rule out in 1 day. I mean, that's -- it's shocking that we've been able to do that. Well, it's the same as eXoZymes right now.

So what happened was eXoZymes has a toolkit of these enzymes. They understand how to manufacture enzymes, and they understand these pathways of how to make a drug using enzymes or make a compound making enzymes using enzymes. AI just supercharged it because they were able to now utilize much more data that they have to get to an answer quicker. So their ability to effectively prototype a new drug has gone from in the old synthetic biology taking years to do, they can do it in sometimes days. That's how powerful this is. It's going to have a massively profound impact on new drugs and treating disease that goes well beyond eXoZymes.

But eXoZymes has a toolkit with known compounds and known pathways to be able to get there so fast. And that's what's exciting. And I think that now that we've shown the ability to scale manufacturing, drug companies have to be interested in this. And we've got to get out, and that's why I said we've got to get partnerships done with drug companies because we have it now. We have the ability to make compounds that they need to fill their pipeline with that you can't just go get from other people. We have a unique capability at eXoZymes that no other synbio company has. And super exciting time.

I mean, we're going to hit on one of these drugs that's going to really open the sky for the company, I think. It's a very, very exciting time for eXoZymes.

George Brandon: Where do they -- how do you -- from the pharmaceutical perspective, how long does it take to gin up some interest, whether the cannabinoids or a new molecule? For those that aren't really -- that don't understand that pharmaceutical pathway, what would that look like? And where do you think that eXoZymes is with that?

Christopher Marlett: They have the ability to manufacture small quantities quickly so they can be tested very quickly in animals. Again, many of these compounds are not easy to make. Even the drug that Paulex is putting in the clinic, it's a small molecule, but it wasn't trivial to manufacture that drug. It actually took time to get clean manufacturing for that drug. And we're going to be able to dramatically enhance that and get these things in the clinic quickly so we can test them preclinically, which then gives big pharma the confidence to put it into the clinic with humans quickly. So I think the cycle can be much faster.

And we've seen some of these AI, let's call it, drug discovery platforms doing big deals with folks like Anthropic and others. And we think that's totally possible for eXoZymes as well.

George Brandon: So a question on the large position -- we have a large position in all 4 of these, smaller in Buda and smaller in HeartBeam, but large in those 4. What -- can you kind of describe what your thinking is on the distribution strategy? What you -- if you just get to an inflection point, what that -- what you mean by that?

Christopher Marlett: Well, I think that -- I'm hoping that eXoZymes gets to an inflection point in 2027 so that we -- it's already public, it would be very easy to distribute. We would -- once it gets to that inflection point, they've got their financings done per se, then that's a good time to distribute. So hopefully, that's -- we're hoping that, that all happens and we can make that distribution of those shares to the shareholders very soon. So that's an easy one. The other ones are not public yet. So the idea of getting them public is important to us.

And we have -- we are talking about a way to get Public Ventures public in a partnership, and we're looking at that. And we're also looking at PatentVest and potentially taking that public as well. So if we do, then it's easy to distribute those assets. And so our first priority being that we're in the public venture business to get these companies public. And so that's the easiest way.

George Brandon: Do you worry that if you do that early, it would put pressure on the stock? Is that why you look at them? You'd want them to be healthy trading volume, well financed, what do you think?

Christopher Marlett: Yes. eXoZymes is not trading much volume. It hasn't gotten that real hot yet based on commercialization or an inflection point. But when it does, we've had in the history when these things really hit, they trade millions of shares a day. So distributing out millions of shares is not going to negatively impact them.

George Brandon: Right. Paulex questions. So the Paulex is going into -- as you said, into people here later this year. What do you -- why -- where is the confidence as far as that this drug that we -- on the data we have so far has a better probability of working in, say, a cancer drug? Do you have any kind of a feel for that? Why you're confident that this might have a higher probability of actually showing some success in people?

Christopher Marlett: Well, listen, it's been validated this pathway. It basically enables, takes the brake off producing beta cells. And it's been shown with human cells, in animals, but -- and that's a big thing. I mean, that's never been done with a drug ever, and so -- safely, that is. It was done with a drug unsafely, and it got pulled off the market, but -- they got pulled out of trials, I should say. But if we can do it safely, then that's Holy Grail. I mean, I don't know -- it doesn't get any bigger than that in my mind.

GLP-1s are big, but this will be, to me, a whole new category that we could be the leader in. So it's -- we're super close to knowing it. I mean, we're very close to knowing if it's safe, and we're also pretty darn close to knowing whether it grows beta cells, too. So it's an exciting time. It's sort of like -- it's exciting, and it's a great time. I mean, if it works, it's going to be transformative.

George Brandon: So that's pretty much it. We covered generally the questions here. I'm going to go ahead and put it back to you and go ahead and close out, Chris.

Christopher Marlett: We covered all the questions already.

George Brandon: Yes.

Christopher Marlett: All right.

George Brandon: Well, wait. I don't understand the last question, so I'm going to go ahead and pass on it.

Christopher Marlett: Okay. All right, guys. Well, we're working our tails off to get these companies to an inflection point, get them to be super valuable companies as we've done with a lot of our companies in the past. We're excited. We're also -- we're stressed as well. I mean, the market has not been kind to these companies and to us. But it doesn't change what we're doing. We're coming to work every day. We're really excited about the prospects, and we just keep hammering away every day to get these companies to that level. And we really appreciate you all sticking in there with us, joining a conference call, listening to us, participating in our offerings.

It's been a really trying time for all of us, but we're -- nothing good is easy, and we're still just as excited about all these companies and the mission that we undertook when we went public. So thanks again.

Tony Dammicci: Thank you, everybody. This concludes today's webinar.

Should you buy stock in Mdb Capital right now?

Before you buy stock in Mdb Capital, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Mdb Capital wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $321,850!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $955,232!*

Now, it’s worth noting Stock Advisor’s total average return is 793% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 18, 2026.

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Gold Price Today: XAU/USD Breaks Below $3,800 | Mitrade AUGold falls below US$3,800 as Fed rate-hike expectations weigh. Explore XAU/USD levels, upcoming Fed minutes and the outlook for Australian traders.
Author  Mitrade Team
10 hours ago
Gold falls below US$3,800 as Fed rate-hike expectations weigh. Explore XAU/USD levels, upcoming Fed minutes and the outlook for Australian traders.
placeholder
Market News Today Australia: Gold Below US$3,900, US Stocks Fall as Nvidia Delivers Strong EarningsUS retail sales rise 0.2%, gold stays below US$3,900 and Nvidia beats earnings estimates. Explore the outlook for Australian CFD traders.
Author  Mitrade Team
15 hours ago
US retail sales rise 0.2%, gold stays below US$3,900 and Nvidia beats earnings estimates. Explore the outlook for Australian CFD traders.
placeholder
Gold Price Today: Can XAU/USD Hold $3,870? | Mitrade AUGold rebounds near US$3,870 after hitting a one-year low. Explore XAU/USD support, Fed risks and what the outlook means for Australian traders.
Author  Mitrade Team
Yesterday 08: 50
Gold rebounds near US$3,870 after hitting a one-year low. Explore XAU/USD support, Fed risks and what the outlook means for Australian traders.
placeholder
Nvidia faces its biggest earnings test yet — why Silicon Valley billionaires want Jensen Huang backNvidia faces a critical earnings test as investors weigh its AI growth outlook and leadership uncertainty. Discover why Silicon Valley billionaires want Jensen Huang back, what it could mean for Nvidia shares and how the results may shape the broader AI trade.
Author  Mark Garro
Yesterday 03: 24
Nvidia faces a critical earnings test as investors weigh its AI growth outlook and leadership uncertainty. Discover why Silicon Valley billionaires want Jensen Huang back, what it could mean for Nvidia shares and how the results may shape the broader AI trade.
placeholder
Berkshire Hathaway's Only New Q3 Position Is a Company Few Investors RecognizeBerkshire Hathaway’s only new third-quarter position is a Bending Spoons stake worth $689 million on Sept. 30. The Italian company, listed on Nasdaq as BSP, owns AOL, Evernote, and Vimeo.Berkshire’s F
Author  Beincrypto
Yesterday 02: 51
Berkshire Hathaway’s only new third-quarter position is a Bending Spoons stake worth $689 million on Sept. 30. The Italian company, listed on Nasdaq as BSP, owns AOL, Evernote, and Vimeo.Berkshire’s F
goTop
quote